A compelling case for central pathology review of multiparameter flow cytometry measurable residual disease results in Acute Myeloid Leukemia (AML) clinical trials: Data from the PALG-AML1/2016 multicenter randomized studyAgnieszka Wierzbowska, Gail J. Roboz, Martyna Włodarczyk et al.|Blood|2025Cited by 1
A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)Agnieszka Wierzbowska, Gail J. Roboz, Anna Czyż et al.|Blood|2022Cited by 0
DAC and CLAM are equally effective as early second induction in newly diagnosed AML patients with persistent leukemia in early bone marrow evaluation – a retrospective analysis of Polish Adult Leukemia GroupKamil Brzozowski, Agnieszka Wierzbowska, Agnieszka Pluta et al.|Acta Haematologica Polonica|2024Cited by 0
Tyrosine kinase inhibitors, low intensity chemotherapy and allohct for adults with Philadelphia-positive acute lymphoblastic leukemia. Results of the polish adult leukemia group (PALG) ALL7 protocolSebastian Giebel, Anna Czyż, Elżbieta Patkowska et al.|Blood|2025Cited by 0
Prospective assessment of measurable residual disease kinetics in intensively treated patients with Acute Myeloid Leukemia (AML) - results of the PALG-AML1/2016 studyAgnieszka Wierzbowska, Gail J. Roboz, Agnieszka Pluta et al.|Blood|2025Cited by 0